CompletedNot Applicable

ADAM17 and Vascular Function in Diabetes

United States36 participantsStarted 2023-03-01

Plain-language summary

The objective of this project is to determine the extent to which administration of the dietary supplement phosphatidylserine (PS), a competitive inhibitor of ADAM17 sheddase activity, effects vascular function and insulin-stimulated leg blood flow in subjects with T2D.

Who can participate

Age range45 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Men and women with a BMI of 25-39 kg/m2, who are 45-64 years of age at randomization.
✓. T2D patients classified based on physician diagnosis.
✓. No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.

Exclusion criteria

✕. Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
✕. History of chronic renal or hepatic disease
✕. Active cancer
✕. Autoimmune diseases
✕. Immunosuppressant therapy
✕. Hormone replacement therapy
✕. Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
✕. Current tobacco use

What they're measuring

Change in Insulin-stimulated Blood Flow

Timeframe: baseline and 4 weeks

Trial details

NCT IDNCT04557228

SponsorUniversity of Missouri-Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-03

Results submitted2026-02-24

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials